Reynaldo Dietze

Dr. Dietze’s retired in 2017, from his position of Full Professor of Medicine at the Federal University of Espírito Santo (UFES) and Director for Research and Teaching at the University Hospital, to join the Instituto de Higiene e Medicina Tropical (IHMT) at the Universidade Nova de Lisboa as an invited Chair Professor of the Unidade de Ensino e Investigação de Clínica Tropical.  Dr. Dietze’s was also the former Director of the Núcleo de Doenças Infecciosas at the Federal University of Espírito Santo (UFES), Vitória, ES, Brazil for 27 years, where he leaded a multidisciplinary team of investigators studying epidemiology, microbiology, molecular biology and immunology of infectious diseases, in particularly tuberculosis, Dengue and Zika virus infection.  He has also an Honorary Title of Consulting Associate Professor of Medicine and Consulting Director for International Health Program with the Division of Infectious Diseases and International Health, Duke University Medical Center, Durham, NC, USA.

Dr. Dietze was the former President of the Brazilian Society of Tropical Medicine, Clinical Trial Coordinator of the Brazilian Tuberculosis Research Network, Member of the Tuberculosis Committee at the TB National Program/Ministry of Health.  He has been involved in numerous phase 2/3 clinical trials in Tuberculosis, Dengue, Schistosomiasis, Leishmaniasis, Sporotrichosis, and Candidiasis in immunosuppressed patients.  Dr. Dietze was the Principal Investigator of several Walter Reed Army Institute of Research (WRAIR) and NIH-funded grants, which resulted in a number of important publications. Dr. Dietze is highly experienced in clinical trials design and has implemented multiple trials under IND from the US FDA. These are all consistent with Dr. Dietze’s new position as a Chair Professor at the IHMT where his is committed to improve the quality of clinical research in Tropical Medicine not only at his new host institution but also in African countries (Mozambique, Angola and Guinea Bissau) where the IHMT has collaborating sites.

1. Carnielli JBT, Crouch K, Forrester S, Silva VC, Carvalho SFG, Damasceno JD, Brown E, Dickens NJ, Costa DL, Costa CHN, Dietze R, Jeffares DC, Mottram JC. A Leishmania infantum genetic marker associated with miltefosine treatment failure for visceral leishmaniasis.  EBioMedicine. 36:83-91. doi: 10.1h016/j.ebiom.2018.09.029, 2018.
2. Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD, Chakravorty S, Gupta A, Sizemore EE, Diem L, Sherman DR, Okwera A, Dietze R, Boom WH, Johnson JL, Mac Kenzie WR, Alland D; DMID 01-009/Tuberculosis Trials Consortium Study 22 Teams. Bacterial Factors That Predict Relapse after Tuberculosis Therapy. N Engl J Med. 30;379(9):823-833. doi: 10.1056/NEJMoa1715849, 2018.
3. Chrusciak-Talhari A, Dietze R, Chrusciak Talhari C, da Silva RM, Gadelha Yamashita EP, de Oliveira Penna G, Lima Machado PR, Talhari S.  Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil.  Am J Trop Med Hyg 84(2):255-60, 2011.
4. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R.  Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis.  Int J Tuberc Lung Dis 10(6):605-12, 2006.
5. Dietze R, Fagundes SM, Brito EF, Milan EP, Feitosa TF, Suassuna FA, Fonschiffrey G, Ksionski G, Dember J.  Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days.  Trans R Soc Trop Med Hyg 89(3):309-11, 1995.